SLC45A3: Difference between revisions
Jump to navigation
Jump to search
m (Bot: HTTP→HTTPS) |
imported>Rjwilmsi (→Further reading: 10.1593/neo.09572) |
||
| Line 13: | Line 13: | ||
==Further reading== | ==Further reading== | ||
{{refbegin | 2}} | {{refbegin | 2}} | ||
*{{cite journal |vauthors=Pflueger D, Rickman DS, Sboner A, etal |title=N-myc downstream regulated gene 1 (NDRG1) is fused to ERG in prostate cancer. |journal=Neoplasia |volume=11 |issue= 8 |pages= 804–11 |year= 2009 |pmid= 19649210 |doi= |pmc=2713587}} | *{{cite journal |vauthors=Pflueger D, Rickman DS, Sboner A, etal |title=N-myc downstream regulated gene 1 (NDRG1) is fused to ERG in prostate cancer. |journal=Neoplasia |volume=11 |issue= 8 |pages= 804–11 |year= 2009 |pmid= 19649210 |doi=10.1593/neo.09572 |pmc=2713587}} | ||
*{{cite journal |vauthors=Helgeson BE, Tomlins SA, Shah N, etal |title=Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer. |journal=Cancer Res. |volume=68 |issue= 1 |pages= 73–80 |year= 2008 |pmid= 18172298 |doi= 10.1158/0008-5472.CAN-07-5352 }} | *{{cite journal |vauthors=Helgeson BE, Tomlins SA, Shah N, etal |title=Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer. |journal=Cancer Res. |volume=68 |issue= 1 |pages= 73–80 |year= 2008 |pmid= 18172298 |doi= 10.1158/0008-5472.CAN-07-5352 }} | ||
*{{cite journal |vauthors=Gerhard DS, Wagner L, Feingold EA, etal |title=The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). |journal=Genome Res. |volume=14 |issue= 10B |pages= 2121–7 |year= 2004 |pmid= 15489334 |doi= 10.1101/gr.2596504 |pmc=528928}} | *{{cite journal |vauthors=Gerhard DS, Wagner L, Feingold EA, etal |title=The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). |journal=Genome Res. |volume=14 |issue= 10B |pages= 2121–7 |year= 2004 |pmid= 15489334 |doi= 10.1101/gr.2596504 |pmc=528928}} | ||
Latest revision as of 16:44, 4 January 2018
| VALUE_ERROR (nil) | |||||||
|---|---|---|---|---|---|---|---|
| Identifiers | |||||||
| Aliases | |||||||
| External IDs | GeneCards: [1] | ||||||
| Orthologs | |||||||
| Species | Human | Mouse | |||||
| Entrez |
|
| |||||
| Ensembl |
|
| |||||
| UniProt |
|
| |||||
| RefSeq (mRNA) |
|
| |||||
| RefSeq (protein) |
|
| |||||
| Location (UCSC) | n/a | n/a | |||||
| PubMed search | n/a | n/a | |||||
| Wikidata | |||||||
| |||||||
Solute carrier family 45 member 3 (SLC45A3), also known as prostate cancer-associated protein 6 or prostein, is a protein that in humans is encoded by the SLC45A3 gene.[1][2][3]
SLC45A3 is expressed in a prostate-specific manner by normal tissues and at a significantly lower level in prostate tumor cell lines. Treatment prostate cancer cell lines with androgens upregulates the expression of SLC45A3.[3]
Regulation
There is evidence that the expression of SLC45A3 is regulated by the microRNA mir-126*.[4]
References
- ↑ "Entrez Gene: solute carrier family 45".
- ↑ Walker MG; Volkmuth W; Sprinzak E; Hodgson D; Klingler T (December 1999). "Prediction of gene function by genome-scale expression analysis: prostate cancer-associated genes". Genome Res. 9 (12): 1198–203. doi:10.1101/gr.9.12.1198. PMC 310991. PMID 10613842.
- ↑ 3.0 3.1 Xu J; Kalos M; Stolk JA; Zasloff EJ; Zhang X; Houghton RL; Filho AM; Nolasco M; Badaró R; Reed SG (February 2001). "Identification and characterization of prostein, a novel prostate-specific protein". Cancer Res. 61 (4): 1563–8. PMID 11245466.
- ↑ Musiyenko A; Bitko V; Barik S (2008). "Ectopic expression of miR-126*, an intronic product of the vascular endothelial EGF-like 7 gene, regulates prostein translation and invasiveness of prostate cancer LNCaP cells". J Mol Med. 86 (3): 313–22. doi:10.1007/s00109-007-0296-9. PMC 3263384. PMID 18193184.
Further reading
- Pflueger D, Rickman DS, Sboner A, et al. (2009). "N-myc downstream regulated gene 1 (NDRG1) is fused to ERG in prostate cancer". Neoplasia. 11 (8): 804–11. doi:10.1593/neo.09572. PMC 2713587. PMID 19649210.
- Helgeson BE, Tomlins SA, Shah N, et al. (2008). "Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer". Cancer Res. 68 (1): 73–80. doi:10.1158/0008-5472.CAN-07-5352. PMID 18172298.
- Gerhard DS, Wagner L, Feingold EA, et al. (2004). "The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)". Genome Res. 14 (10B): 2121–7. doi:10.1101/gr.2596504. PMC 528928. PMID 15489334.
- Esgueva R, Perner S, J LaFargue C, et al. (2010). "Prevalence of TMPRSS2-ERG and SLC45A3-ERG gene fusions in a large prostatectomy cohort". Mod. Pathol. 23 (4): 539–46. doi:10.1038/modpathol.2009.193. PMC 2848699. PMID 20118910.
- Strausberg RL, Feingold EA, Grouse LH, et al. (2002). "Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences". Proc. Natl. Acad. Sci. U.S.A. 99 (26): 16899–903. doi:10.1073/pnas.242603899. PMC 139241. PMID 12477932.
- Kimura K, Wakamatsu A, Suzuki Y, et al. (2006). "Diversification of transcriptional modulation: large-scale identification and characterization of putative alternative promoters of human genes". Genome Res. 16 (1): 55–65. doi:10.1101/gr.4039406. PMC 1356129. PMID 16344560.
- Friedman RS; Spies AG; Kalos M (2004). "Identification of naturally processed CD8 T cell epitopes from prostein, a prostate tissue-specific vaccine candidate". Eur. J. Immunol. 34 (4): 1091–101. doi:10.1002/eji.200324768. PMID 15048720.
- Maher CA, Kumar-Sinha C, Cao X, et al. (2009). "Transcriptome sequencing to detect gene fusions in cancer". Nature. 458 (7234): 97–101. doi:10.1038/nature07638. PMC 2725402. PMID 19136943.
- Musiyenko A; Bitko V; Barik S (2008). "Ectopic expression of miR-126*, an intronic product of the vascular endothelial EGF-like 7 gene, regulates prostein translation and invasiveness of prostate cancer LNCaP cells". J. Mol. Med. 86 (3): 313–22. doi:10.1007/s00109-007-0296-9. PMC 3263384. PMID 18193184.
- Kiessling A; Stevanovic S; Füssel S; Weigle B; Rieger MA; Temme A; Rieber EP; Schmitz M (March 2004). "Identification of an HLA-A*0201-restricted T-cell epitope derived from the prostate cancer-associated protein prostein". Br. J. Cancer. 90 (5): 1034–40. doi:10.1038/sj.bjc.6601642. PMC 2410218. PMID 14997204.
- Satake W, Nakabayashi Y, Mizuta I, et al. (2009). "Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease". Nat. Genet. 41 (12): 1303–7. doi:10.1038/ng.485. PMID 19915576.
- Kalos M, Askaa J, Hylander BL, et al. (2004). "Prostein expression is highly restricted to normal and malignant prostate tissues". Prostate. 60 (3): 246–56. doi:10.1002/pros.20043. PMID 15176054.
- Sheridan T; Herawi M; Epstein JI; Illei PB (2007). "The role of P501S and PSA in the diagnosis of metastatic adenocarcinoma of the prostate". Am. J. Surg. Pathol. 31 (9): 1351–5. doi:10.1097/PAS.0b013e3180536678. PMID 17721190.
 | This article on a gene on human chromosome 1 is a stub. You can help Wikipedia by expanding it. |